anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study only contains 1 arm. All participants will receive the same experimental protocol. Participants will receive daily text messages and bi-weekly newsletters for reducing sedentary behavior based on Social Cognitive Theory.
In the operation of distal radial fractures, the volar plating techniques become popular. During the surgical approach, the pronator quadratus (PQ) muscle needs split or full-thickness strip to exposure the fracture site and facilitate the instrumentation of the plate. Generally, the PQ would be repaired. Sometimes, the PQ is damaged by the fracture fragment so severely that it is difficult to repair the PQ. However, there is few reviews paper to discuss the consequence of the unrepaired or repaired PQ and the AAOS guideline1 of the treatment of distal radial fracture in 2009 did not even list the management of the PQ. The function of the PQ includes pronation and stability of the distal radial-ulnar joint (DRUJ). According to the study, the elimination of PQ function will cause a significant decrease in pronation torque, which is supposed to affect the function of the wrist in the daily life. The theoretical benefits of the repair of the pronator quadratus include flexor tendon protection3,4, remain of the normal pronation-supination range of motion (ROM) and strength, and keeping the stable DRUJ.
PURPOSE:To normalize the fermentation in intestine and to eliminate active oxygen by incorporating a specific dissolved oxygen in a formed water formed at the cathode side by electrolysis of water with a partition to accelerate reducing reaction in living body. CONSTITUTION:The dissolved oxygen of 2-6ppm is incorporated in the formed water formed at the cathode by electrolysis of water with partition. And the dissolved oxygen has -100-(-750)mV oxidation reduction potential and the formed water having hydrogen ion concn. of pH7.5-10 is used. By drinking the electrolytically formed water having low concn. dissolved oxygen in this way, the activity of active oxygen in living body is suppressed, the function as a scavenger is accelerated and the effect of medical care effective for sickness by metabolic disease or sickness by immunological function lesion observed in antigen-antibody reaction is shown.
Coffee is one of the most widely consumed beverages. It contains polyphenols (chlorogenic acids) and bioavailability of these bioactive compounds is now somewhat well understood. However, even if chlorogenic acids are known to be antioxidants in the cup, reliable evidence remains to be observed in vivo.

After medical examination and approval, subjects will undergo 2 periods of 21 days. The first 7 days will consist of a dietary restriction to lower the polyphenols intake. Then subjects will drink at random one of the three treatments for 14 days (4 cups/day). Blood and urine samples will be collected throughout the study to evaluate in vivo effects on oxidative biomarkers. Furthermore, at day 21, subjects will undergo a physical regimen to increase acutely and transiently their oxidative damage. Blood and urine samples collected throughout this challenge will allow us to evaluate the effect of coffee intake in reducing oxidative damage created by exercise compared to placebo.
The invention discloses an application of metformin in preparing a medicament for treating testicle spermatogenic dysfunction, and belongs to the technical field of biological medicines. The invention discovers that after MET treatment, the number of sperms in testes of the diabetic mice is obviously increased, vacuolation in seminiferous tubules is recovered, the thickness of seminiferous epithelium is increased, the arrangement of sperm cells at all levels is orderly, and the morphology in testes of the mice is basically recovered. The testis, epididymis and seminal vesicle indexes of the mice are obviously increased, the estradiol is obviously reduced, the sperm survival rate is obviously improved, the proliferation condition of spermatogenic cells is obviously recovered, the expression of proliferation related protein PCNA in testis tissues is obviously increased, the expression content of AMPK and mTOR in the testis is increased, and the phosphorylation level is increased. The levels of phosphorylation of S6 and S6K downstream of AMPK/mTOR are increased. The sperm-egg binding rate and the fertilized egg cell division in the in vitro fertilization experiment are increased, and the conception rate of female mice is increased. Can be used for treating testis seminiferous dysfunction of type 2 diabetes mice.
The number of total joint arthroplasties performed in the United States is increasing every year. Owing to the aging population and excellent long-term prosthesis survival, 45% of patients who undergo joint arthroplasty will receive two or more joint arthroplasties during their lifetimes. Periprosthetic joint infection (PJI) is among the most common complications after arthroplasty. Evaluation and treatment of PJI in patients with multiple joint arthroplasties is challenging, and no consensus exists for the optimal management. Multiple PJI can occur simultaneously, synchronous, or separated by extended time, metachronous. Patient risk factors for both scenarios have been reported and may guide evaluation and long-term management. Whether to perform joint aspiration for asymptomatic prosthesis in the presence of suspected PJI in patients with multiple joint arthroplasties is controversial. Furthermore, no consensus exists regarding whether patients who have multiple joint arthroplasties and develop PJI in a single joint should be considered for prolonged antibiotic prophylaxis to reduce the risk of future infections. Finally, the optimal treatment of synchronous joint infections whether by débridement, antibiotics and implant retention, and one-stage or two-stage revision has not been defined. This review will summarize the best information available and provide pragmatic management strategies.
The identification of rare genetic variants associated to Systemic Lupus Erythematosus (SLE) could also help to understand the pathogenic mechanisms at the basis of the disease. In this study we have analyzed a cohort of 200 Italian SLE patients in order to explore the rare protein-coding variants in five genes (TNFAIP3, STAT4, IL10, TRAF3IP2, and HCP5) already investigated for commons variants found associated in our previous studies. Genomic DNA of 200 SLE patients was sequenced by whole exome sequencing. The identified variants were filtered by frequency and evaluated by in silico predictions. Allelic association analysis was performed with standard Fisher's exact test. Introducing a cutoff at MAF < 0.01, a total of 19 rare variants were identified. Seven of these variants were ultra-rare (MAF < 0.001) and six were absent in the GnomAD database. For TNFAIP3 gene, the variant c.A1939C was observed in 4 SLE patients and it is located in a region enriched in phosphorylation sites and affects the predict affinity of specific kinases. In TRAF3IP2 gene, we observed 5 different rare variants, including the novel variant c.G410A, located in the region that mediates interaction with TRAF6, and therefore a possible risk factor for SLE development. In STAT4 gene, we identified 6 different rare variants. Among these, three missense variants decrease the stability of this protein. Moreover, 3 novel rare variants were detected in 3 SLE patients. In particular, c.A767T variant was predicted as damaging by six prediction tools. Concluding, we have observed that even in genes whose common variability is associated with SLE susceptibility, it is possible to identify rare variants that could have a strong effect in the disease development and could therefore allow a better understanding of the functional domain involved.
Of the total number of subjects in clinical studies of levetiracetam, 347 were 65 and over. No overall differences in safety were observed between these subjects and younger subjects. There were insufficient numbers of elderly subjects in controlled trials of epilepsy to adequately assess the effectiveness of levetiracetam in these patients.

A study in 16 elderly subjects (age 61-88 years) with oral administration of single dose and multiple twice-daily doses for 10 days showed no pharmacokinetic differences related to age alone.

Levetiracetam is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
For treatment of acute episodes of bronchospasm or prevention of asthmatic symptoms, the usual dosage for adults and pediatric patients 4 years and older is two inhalations repeated every four to six hours; in some patients, one inhalation every four hours may be sufficient. More frequent administration or a larger number of inhalations are not recommended. It is recommended to "test spray" Albuterol Inhalation Aerosol into the air before using for the first time and in cases where the aerosol has not been used for a prolonged period of time.

The use of Albuterol Inhalation Aerosol can be continued as medically indicated to control recurring bouts of bronchospasm. During this time most patients gain optimal benefit from regular use of the inhaler. Safe usage for periods extending over several years has been documented.

If a previously effective dosage regimen fails to provide the usual response, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids.
PURPOSE: A composition for preventing and treating diabetes containing blackchokeberry extract is provided to reduce TBARS concentration and normalize carbon hydrate metabolism. CONSTITUTION: A composition for preventing and treating diabetes contains blackchokeberry extract as an active ingredient. The blackchokeberry extract contains anthocyanin. Diabetes is occurred by strptozotocin. The diabetes is unregulated insulin-dependent diabetes. The composition is used in the form of pill, capsule, drink or medicinal and pharmaceutical product.
TAU (n = 51) In the acute care setting, the Behavioral Health Service provides SBIRT for substance use disorders, including OUD. They provide SBIRT as part of TAU, including a warm handoff to an outpatient MOUD treatment with a scheduled outpatient appointment, optimally within 48 hours of the ED visit. TAU outpatient suboxone treatment consists of urine toxicology screening, group/individual therapy, and MOUD prescription continent on drug-negative urine toxicology. Treatment visits are typically weekly in weeks 1-4 and then taper over time, to every other week in weeks 5-8, and monthly in weeks 9-12 and after. Nonadherence can lead to increased frequency/intensity of therapy and urine toxicology until the patient stabilizes. If increased frequency/intensity is unsuccessful, patients may be referred to detoxification and subsequently re-admitted to outpatient care when appropriate. Patients will receive MyMAT a mobile application with educational content regarding MOUD treatment.
The present invention relates to an epilepsy recovering pill and a preparation method thereof. The epilepsy recovering pill is a traditional Chinese medicine which is used for treating epilepsy disease symptoms. The epilepsy recovering pill is prepared from eighteen traditional Chinese medicinal materials, such as uncaria, gastrodia tuber, concha haliotidis, earthworm, Indian bread with hostwood, alum, curcuma root, lapis chloriti, calculus bovis, grassleaf sweetflag rhizome, lodestone, rhubarb, coptis, tabasheer, bile arisaema, centipede, scorpion, musk, etc., and the pill is prepared after pulverization and mixing. The recovering pill has the advantages of favorable treating effects, practical and reliable treating effects, no toxic or side effects and high treating rate. The epilepsy recovering pill can particularly have obvious treating effects on child patients. The effective rate is more than 90%, and intellectual development of the patients can not be affected.
A hard shell capsule includes a body and a cap cooperatively defining a hollow core hard shell capsule. Each of the body and the cap has a composition that includes a polymer forming a hard polymer structure of the body and of the cap and comprises a drug. The body further comprises a therapeutically effective amount of drug A loaded throughout the composition; the cap further comprises a composition comprising a therapeutically effective amount of drug B loaded throughout the composition. The body and cap compositions together containing a therapeutically effective amount of the drugs A and B; said drugs being oral contraceptive agents. The core of the capsule is filled with therapeutically effective amount of a second drug(s), a dietary supplement, minerals, a complexing agent and other excipients. With the help of FIG. 2, the invention can be very well understood easily. Drugs A and B are selected from the group of oral contraceptives, but are not limited to, Cyproterone acetate, Estradiol, Oestradiol, Norethindrone acetate, Ethinyl Estradiol, Levonorgestrel, Dienogest, Drospirenone, Desogestrel, Ethynodiol, Diacetate, Mestranol, Nomegestrol acetate, Norgestrel, Norgestimate, Dienogest, Norelgestromin, Norethisterone, Gestodene, Oestradiol valerate, and Ethynodiol diacetate.
The FSET Anxiety and Sleep Treatment (FAST) is a brief, 45-minute computerized intervention that can be accessed by any device connected to the Internet. The majority of the information is delivered via text. The program contains some interactive features such as quizzes, which direct participants to content, personalized to the individual user (for example screenshots, see Figure 2). FAST contains four modules: motivation, psychoeducation, behavioral tools, and behavior change.
PRASTERA® may cause acne. This acne is reversible on cessation of prasterone therapy, and may be treateable by a topical anti-acne drug. You may request a Prastera® convenience kit which includes a topical anti-acne drug. 

PRASTERA® may cause hirsutism, reversible on cessation of prasterone therapy. 

PRASTERA® may cause hypertension, §6.3.2, and/or changes in serum lipids, §7.2.4, or serum hormone levels, §7.2.1. These should be monitored, and are reversible on cessation of prasterone therapy.
Phase 2 (4 weeks): Both groups underwent a month-long "wash out" period, during which they did not ingest any of the Supplement or Placebo. This lasted from weeks 9-12. This phase was not double-blinded as all participants and the researchers were aware of the wash-out procedure.
The project is designed to evaluate Mom-Net, an internet-facilitated cognitive-behavioral (CBT) intervention for depression, adapted from Lewinsohn's Coping with Depression Course, and tailored to mothers of young children. Mom-Net, which was developed and piloted in a recently completed NIMH-funded investigation (MH070426), was designed to overcome the substantial barriers to treatment participation that exist for mothers experiencing economic hardship and those in rural communities. Though the pilot trial demonstrated that the program was very effective in reducing depressive symptoms and related difficulties, it was conducted under the 'idealized' conditions typical of initial intervention tests (e.g., computers and internet connections were supplied to all participants; access to the internet was provided by a single browser; coaches who provided weekly phone support were research staff, and initial recruitment and motivational interviews sessions were conducted via home visits to participants). These conditions likely facilitated recruitment and retention of participants, as well as ease and fidelity of treatment delivery. Thus one goal of the current project is to evaluate the intervention under conditions that are closer to those of real-world service providers and recipients. The current project is also intended to provide a more rigorous test of the intervention than did the pilot in a number of ways. Participants in this project will be 300 mothers of 3-5 year old children recruited through Head Start classrooms and prescreened for the presence of elevated depressive symptoms. Subsequent to the pre-intervention assessment, participants will be randomized to either the intervention or facilitated usual care (FUC) condition. The evaluation of the intervention will focus on maternal depressive symptoms, parenting behavior, and child adjustment. Two follow-up assessments (at 12-month and 24-month intervals) will enable us to examine maintenance of effects. Overall, the investigation will contribute to the evidentiary base regarding the dissemination potential of this empirically-supported intervention, adaptations to which have the potential to enable a greater proportion of the population to access and benefit from it.
Despite substantial advancements in wound dressing development, effective skin repair remains a significant challenge, largely due to the persistent issue of recurrent infections. Three-dimensional printed constructs that integrate bioactive and antibacterial agents hold significant potential to address this challenge. In this study, a 3D-printed hydrogel scaffold composed of polyallylamine hydrochloride (PAH) and pectin (Pc), incorporated with mupirocin (Mp)-loaded quaternized chitosan nanoparticles (QC NPs) was fabricated. The primary objective of this study was to facilitate a controlled and sustained release of Mp via the QC NPs. The average size of QC-Mp nanoparticles was measured to be 66.05 nm and the average strand diameter and pore size of the 3D-printed construct were measured as 147.22 ± 5.83 and 388.44 ± 14.50 μm, respectively. The hemolysis rate of all scaffolds was below 2 %, indicating that they can be classified as non-hemolytic materials with sufficient blood compatibility. The PAH-Pc/QC-Mp scaffold exhibited significant antibacterial activity, enhanced cell viability in HaCat cells, sustained Mp release until day 7 (⁓60 %), and in-vivo wound healing promotion by stimulation of human keratinocytes. In conclusion, the proposed biocompatible construct demonstrates significant potential for the treatment of chronic and infected wounds by preventing infection and promoting accelerated wound healing.
Hypertension and obesity or overweight related, even other associated comorbidities, involve a worrying public health problem. The evidence shows that healthy eating and regular physical exercise, monitored by different means (internet, face to face, exercise diaries), play an important prevention role to maintain health while ageing. In this way, Information and Communication Technologies (ICTs) have been demonstrated as a useful tool to promote health, working on barriers at the same time, such as low motivation and difficulties to maintain regular exercise or healthy eating habits. ICTs also allows to reach a wider audience at a lower cost, due to their good cost-benefit relationship and the possibility of increasing the efficiency of interventions. Therefore, this study aims to analyze the effects of a 3 months duration self-applied online program, composed of 9 modules focused on promoting healthy lifestyle habits (healthy eating and increased physical activity), on obese or overweight adults with hypertension. Participants will be recruited from a hypertension unit of a public hospital. These patients will be randomized allocated into two interventional groups: experimental group will receive audiovisual instructions from their hypertension specialist doctor, and the control group from a doctor outside the patient. Assessment will include: body composition (BMI), blood pressure, levels of physical activity, functional capacity, fall risk, and quality of life.
PROBLEM TO BE SOLVED: To obtain a new compound, high in frothing power, generating creamy froth, little irritant to hair and skin, good in feeling when applied, e.g. smoothness when used for rinsing, and exhibiting excellent anionic surface-active function when used as a detergent ingredient, even under acidic to weakly alkaline conditions (pH 4 to 8). SOLUTION: This carboxylate is shown by formula I (R is a 6-30C alkyl or the like; X is shown by formula II or III; A is a polyalkylene oxide having an average addition mol number above 1 and 20 or less; Y is H or the like; Z is H or the like; and M is H or the like). The compound shown by formula I is obtained by, e.g. (A) reacting an ester of oxyacid (e.g. glycolic acid) and lower alcohol (preferably methanol or the like) with an alkylene oxide in the presence of basic catalyst (e.g. sodium hydroxide) to form a polyoxyalkylene ether oxyacid ester as the stock compound, (B) reacting the above stock compound with an epoxy alkane or alkene in the presence of basic catalyst, and (C) saponification of the above product with a caustic alkali (e.g. sodium hydroxide).
Systems, methods, and computer program products that enable system-wide probabilistic forecasting, alerting, optimizing and activating resources in the delivery of care to address both immediate (near real-time) conditions as well as probabilistic forecasted operational states of the system over an interval that is selectable from the current time to minutes, hours and coming days or weeks ahead are provided. There are multiple probabilistic future states that are implemented in these different time intervals and these may be implemented concurrently for an instant in time control, near term, and long term. Those forecasts along with their optimized control of hospital capacity may be independently calculated and optimized, such as for a dynamic workflow direction over the next hour and also a patient's stay over a period of days. In the present application, a probabilistic and conditional workflow reasoning system enabling complex team-based decisions that improve capacity, satisfaction, and safety is provided. A means to consume user(s) judgment, implement control on specific resource assignments and tasks in a clinical workflow is enabled, as is the dynamical and optimal control of the other care delivery assets being managed by the system so as to more probably achieve operating criteria such as throughput, waiting and schedule risk. InI 0 cm 6. ra E (EN (0 7:
NEW MATERIAL:A compound of formula I (R is H or 1-5C acyl). EXAMPLE:(4R, 6R, 11aR)-6-acetoxymethyl-4-cyano-7-methoxy-1,3,4,6,11a- hexahydro-2H-benzo[b]quinolidine. USE:Carcinostatics. PREPARATION:Firstly, 2-bromo-1-methyl-3-methoxybenzene of formula II as starting material is brominated and incorporated with nitro group. Second, the nitrile group of the resulting compound is hydrolyzed and esterified, and 5-benzyloxypentanal is added to the resulting compound followed by oxidation and then demethoxycarboxylation. The compound thus formed is enolized, etc., into a compound of formula III, which is then freed from benzyl group, oxidized and then simultaneous elimination of methoxymethyl group and tert.- butoxycarbonyl group followed by addition of a nitrile group.
The present invention is a process of extracting canna plant leaves and the resulting two medicinal chemical compositions thus produced by the process. The process produces a first chemical composition consisting of a water-and-oil extract of dried canna plant leaves and a second chemical composition consisting of the extracted residue from this extraction process. The extract and the extracted residue may be taken orally by a patient, and the extract may also be applied topically. The process consists of extracting dried and pulverized canna plant leaves with a water-and-oil mixture by simmering the leaves in the mixture for about a day. The extract is decanted, filtered and ready for use. The remaining residue is dried, further ground, and encapsulated in gelatin capsules for ease in oral administration.